Synapedia
Back to substances
Deutsch|English

Translated automatically – community improvements welcome.

Fce-26743

Safinamide is a selective, reversible MAO-B inhibitor used for the treatment of Parkinson's disease. It modulates dopaminergic signaling pathways and additionally affects voltage-gated sodium channels, suggesting neuroprotective effects. The substance is primarily used to improve motor symptoms and has a moderate risk profile when used correctly.

Antidepressiva
Antidepressiva
MAO-B
Glutamat-Rezeptoren

Mechanism of Action

  • glutamate modulator
  • MAO-B inhibitor
Detailed mechanism of action

Names / Identifiers

IUPAC: Safinamide

Safinamide
133865-89-1
(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamide
Fce-26743
EMD 1195686
Safinamida
EMD-1195686
90ENL74SIG
2-(4-(3-Fluorobenzyloxy)benzylamino)propionamide
DTXSID601010282

Mechanism of Action

Safinamide wirkt als Hemmer der Monoaminoxidase B (MAO-B) und moduliert die Freisetzung von Glutamat, was zur Verbesserung der Symptome bei Parkinson-Patienten beitragen kann.

Effects

Verbesserung der motorischen Symptome
Reduktion von Dyskinesien
Erhöhung der Lebensqualität
Modulation der Glutamatfreisetzung
Hemmung der Monoaminoxidase B

Effects described from scientific sources. Individual experiences vary.

Dosage

Safety NoteIndividual variation, start at a low dose, no medical advice.

Individual sensitivity varies. Not a dosage recommendation.

Duration

Peak4-6 weeks
NotesThe effect may build up over several weeks.
Onset1-2 weeks
TotalLong-term treatment
After EffectsVariable

Risks & Warnings

Warnings

  • Severe liver disease
  • Concurrent use of MAO inhibitors

Known Risks

  • medium
  • Mögliche Nebenwirkungen umfassen Übelkeit, Schwindel und Schlafstörungen.

Safer Use

  • Medical supervision during intake should be observed.
  • Be aware of interactions with other medications.

Harm reduction tips do not replace medical advice.

Known Interactions

  • Serotonin reuptake inhibitors
  • Dopamine agonists

This list is not exhaustive. Interactions can have unpredictable effects.

Legal Status

ATVerschreibungspflichtig
CHVerschreibungspflichtig
DEVerschreibungspflichtig
USVerschreibungspflichtig
NotesSafinamide ist in vielen Ländern als Medikament zur Behandlung der Parkinson-Krankheit zugelassen.

Not legal advice. Status may change.

Receptor Targets

MAO-B

Monoaminoxidase B (MAO-B) ist ein mitochondriales Enzym, das bevorzugt Phenylethylamin, Benzylamin und Dopamin abbaut. Selektive MAO-B-Hemmer werden bei Morbus Parkinson eingesetzt.

enzyme